Avelumab and Merkel Cell Carcinoma: Biological Plausibility Explained

From General Health Communication to Occupational Exposure Concerns

The legacy of general health and science communication has long emphasized the importance of understanding how environmental and pharmaceutical factors influence population well-being. Historically, public health discourse has focused on broad determinants such as lifestyle, infectious agents, and chemical exposures, often translating complex biomedical concepts into accessible guidance for diverse audiences. This foundational approach has enabled communities to recognize potential risks and engage with preventive measures, from vaccination campaigns to occupational safety protocols. Within this heritage, the transition to examining specific pharmaceutical exposures in occupational settings becomes a natural extension. As therapeutic agents like Avelumab—a monoclonal antibody used in oncology—enter widespread clinical use, questions arise regarding their potential to influence disease processes beyond intended targets. In mass production environments, where workers may encounter pharmaceutical compounds during manufacturing, handling, or disposal, the biological plausibility of exposure-related health outcomes warrants careful consideration. The shift from general health education to occupational exposure concern involves applying the same principles of risk awareness and mechanistic inquiry to workplace contexts, where chronic low-level contact with active substances may present unique challenges. This pivot does not presuppose causation but rather acknowledges the need for systematic evaluation of how pharmaceutical agents interact with biological systems under occupational exposure conditions, maintaining the rigorous, evidence-informed perspective that characterizes effective health communication.

Bridging to Avelumab: Mechanism and Therapeutic Context

Avelumab is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096). It has been approved in the USA, the EU, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis (https://pubmed.ncbi.nlm.nih.gov/33439294; https://pubmed.ncbi.nlm.nih.gov/29799096). The approval was based on the JAVELIN Merkel 200 phase II trial, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096). Despite this therapeutic benefit, avelumab, like other checkpoint inhibitors, can cause overactivation of the immune system, leading to immune-related adverse events (irAEs) (https://pubmed.ncbi.nlm.nih.gov/31543781). These irAEs arise from the drug's mechanism of blocking PD-L1, which normally suppresses T-cell activity; by removing this brake, avelumab can unleash T-cell responses against both tumor cells and normal tissues.

Evaluating Causation: Evidence and Biological Plausibility

The biological plausibility of avelumab causing or contributing to Merkel cell carcinoma is not supported by the available evidence. Instead, the evidence indicates that avelumab is used to treat MCC, not to cause it. Merkel cell carcinoma has two primary etiologies: approximately 80% of cases are caused by the Merkel cell polyomavirus, while the remaining 20% are induced by UV light leading to mutations (https://pubmed.ncbi.nlm.nih.gov/34445385). Avelumab does not introduce this virus or UV damage; rather, it modulates the immune system's ability to recognize and attack existing MCC cells. The drug's mechanism—inhibiting PD-L1 to enhance T-cell responses—is directly aimed at countering the immune evasion strategies of MCC tumors. In fact, avelumab is the first therapeutic agent specifically approved for metastatic MCC, and it is used independent of line of treatment (https://pubmed.ncbi.nlm.nih.gov/29799096). There is no evidence in the provided sources that avelumab induces de novo MCC or transforms benign cells into malignant ones.

Risk Context: Adverse Events vs. Oncogenesis

Regarding causation-related considerations for affected patients, the timeline between avelumab exposure and documented harm must be carefully examined. The reported adverse effects of avelumab in MCC patients include immune-related events such as hypercalcemia due to reactivation of sarcoidosis, which was managed with corticosteroids and allowed continuation of avelumab therapy (https://pubmed.ncbi.nlm.nih.gov/31543781). Additionally, some patients do not respond to avelumab or develop irAEs due to mechanisms such as down-regulation of MHC complexes or induction of anti-inflammatory cytokines (https://pubmed.ncbi.nlm.nih.gov/34445385). However, these are complications of treatment, not evidence that avelumab causes MCC. For patients who are refractory to avelumab, alternative treatments such as combined ipilimumab and nivolumab have shown efficacy, with three out of five patients in one study responding to this regimen (https://pubmed.ncbi.nlm.nih.gov/33439294). The timeline of harm in these cases is typically weeks to months after starting avelumab, consistent with the onset of immune-related adverse events, not with the development of a new malignancy.

Adequacy of Warnings and Clinical Guidance

The adequacy of warnings regarding avelumab and Merkel cell carcinoma is reflected in the drug's approved labeling and clinical guidelines. Avelumab is indicated for the treatment of metastatic MCC, and its prescribing information includes warnings about immune-mediated adverse reactions. The evidence does not suggest that avelumab causes MCC; rather, it is a standard therapy for the disease. Patients and clinicians are informed about the risks of irAEs, which are distinct from the risk of developing MCC. The risk of avelumab-related MCC is not supported by mechanistic pathways or clinical data. Instead, the drug's role is therapeutic, and its adverse effects are primarily immune-related, not oncogenic. In summary, the evidence does not establish a causal link between avelumab and the development of Merkel cell carcinoma. Avelumab is a treatment for MCC, and its biological plausibility for causing the disease is absent. The drug's mechanism of action, clinical trial data, and reported adverse events all point to its role as an immune checkpoint inhibitor used to treat existing MCC, not to induce it. Patients receiving avelumab should be monitored for immune-related adverse events, but there is no evidence that the drug increases the risk of developing MCC.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

Can avelumab cause Merkel cell carcinoma?

No, the available evidence does not support that avelumab causes Merkel cell carcinoma. Avelumab is a treatment for MCC, and its mechanism of action targets PD-L1 to enhance immune response against existing tumor cells. MCC is primarily caused by Merkel cell polyomavirus or UV-induced mutations, not by avelumab.

What are the known adverse effects of avelumab?

Avelumab can cause immune-related adverse events (irAEs) due to overactivation of the immune system, such as hypercalcemia from sarcoidosis reactivation. These are distinct from causing new malignancies. Patients should be monitored for irAEs, which typically occur weeks to months after starting therapy.

Is there any biological plausibility for avelumab causing MCC?

No, the biological plausibility is absent. Avelumab does not introduce the Merkel cell polyomavirus or cause UV-like DNA damage. Its role is to treat existing MCC by blocking PD-L1, not to induce oncogenesis.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel Cell Carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.